Estrogen receptor subtype ratio change protects against podocyte damage.

about

Estrogen receptor subtype ratio change protects against podocyte damage.

Item

http://www.wikidata.org/entity/Q47549327

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Estrogen receptor subtype ratio change protects against podocyte damage.

@en

Estrogen receptor subtype ratio change protects against podocyte damage.

@nl

type

Item

label

Estrogen receptor subtype ratio change protects against podocyte damage.

@en

Estrogen receptor subtype ratio change protects against podocyte damage.

@nl

prefLabel

Estrogen receptor subtype ratio change protects against podocyte damage.

@en

Estrogen receptor subtype ratio change protects against podocyte damage.

@nl

P1476

Estrogen receptor subtype ratio change protects against podocyte damage.

@en

P2093

Paola Catanuto

http://www.w3.org/2001/XMLSchema#string

Sharon Elliot

http://www.w3.org/2001/XMLSchema#string

Simone Pereira-Simon

http://www.w3.org/2001/XMLSchema#string

Xiaomei Xia

http://www.w3.org/2001/XMLSchema#string

P2860

Resveratrol Inhibition of Cellular Respiration: New Paradigm for an Old Mechanism

Anti-Inflammatory and Organ-Protective Effects of Resveratrol in Trauma-Hemorrhagic Injury

17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes

Mitochondrial free radical generation, oxidative stress, and aging

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9.

The Role of SIRT1 in Diabetic Kidney Disease.

Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.

Cancer chemopreventive activity of resveratrol.

Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase.

P304

19-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29367812

http://www.w3.org/2001/XMLSchema#string

P932

5777622

http://www.w3.org/2001/XMLSchema#string